Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print   

Monday 01 August, 2005

XTL Biopharm Ltd

AGM Statement

XTL Biopharmaceuticals Ltd
01 August 2005


Annual General Meeting Statement


Rehovot, Israel, 1 August 2005 - XTL Biopharmaceuticals Ltd. ('XTLbio')
announced that at its Annual General Meeting held earlier today at XTLbio's 
offices, all the resolutions proposed to the shareholders were approved. As 
planned, later today the Company will hold an Extraordinary General Meeting 
(EGM). We will notify the shareholders of the results of the EGM after the 
meeting.

Contacts:

XTLbio
Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

Notes to Editors
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. Established in 1993, XTLbio became a public company in
2000 and its ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange under the symbol XTL and
in the Tel Aviv Stock Exchange, Israel.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
                                                                                                                                                                                                                              

a d v e r t i s e m e n t